Losartan-based therapy v atenolol-based therapy in diabetes with essential hypertension and signs of left ventricular hypertrophy†
| Outcomes | Losartan | Atenolol | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| †Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. ‡Cardiovascular mortality, stroke, and myocardial infarction. | ||||
| Composite end point‡ | 18% | 23% | 22% (2 to 39) | 21 (12 to 250) |
| Cardiovascular mortality | 6% | 10% | 36% (5 to 57) | 28 (18 to 211) |
| All-cause mortality | 11% | 17% | 37% (15 to 53) | 16 (12 to 40) |
| Heart failure | 5% | 9% | 40% (8 to 61) | 28 (19 to 145) |